𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacological considerations in high-dose chemotherapy

✍ Scribed by Yasutsuna Sasaki

Publisher
Springer
Year
1997
Tongue
English
Weight
84 KB
Volume
40
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High-dose chemotherapy in childhood brai
High-dose chemotherapy in childhood brain tumours
✍ C. Kalifa; Dominique Valteau; Barry Pizer; Gilles Vassal; Jacques Grill; Olivier πŸ“‚ Article πŸ“… 1999 πŸ› Springer 🌐 English βš– 55 KB
Clinical pharmacology of high-dose cispl
Clinical pharmacology of high-dose cisplatin
✍ Brian J. Corden; Robert L. Fine; Robert F. Ozols; Jerry M. Collins πŸ“‚ Article πŸ“… 1985 πŸ› Springer 🌐 English βš– 345 KB
Acute renal failure in high dose carbopl
Acute renal failure in high dose carboplatin chemotherapy
✍ Frenkel, Joost ;Kool, Gea ;De Kraker, Jan πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 214 KB

## Abstract Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients. We report a 4 1/2‐year‐old girl who was treated with high‐dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma. Acute renal failure developed followed by a s

High dose chemotherapyβ€”results of Americ
High dose chemotherapyβ€”results of American studies
✍ Craig Nichols; Richard Maziarz πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 74 KB

The role of high dose chemotherapy in the treatment of solid tumors is a subject of robust debate. Opinions range from the adoption of high dose chemotherapy with hematopoietic progenitor support as standard therapy for a number of solid tumors to the view that the application of such expensive and

High dose chemotherapy : Rationale and r
High dose chemotherapy : Rationale and results in breast carcinoma
✍ Robert E. Coleman πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 101 KB

## BACKGROUND. High dose chemotherapy (HDC) with hematopoietic stem cell support is an increasingly important strategy in the management of advanced cancer. Early Phase II studies and the development of peripheral blood stem cell support to enable safe and tolerable myeloablative chemotherapy has